Table 1.
Baseline characteristics at the time of capecitabine treatment
| Patients, N (%) | 162 (100) |
| Line of capecitabine, median (range) | 3.0 (1–9) |
| Age (median) (range) | 61.4 (27.0–85.3) |
| ER status, N (%) | |
| Positive (1–100%) | 115 (71.0) |
| Negative (0%) | 41 (25.3) |
| Unknown | 6 (3.7) |
| Metastatic site, N (%) | |
| Bone only | 18 (11.1) |
| CNS | 10 (6.2) |
| Visceral | 118 (72.8) |
| Other | 16 (9.9) |
| Performance status, N (%) | |
| 0 | 40 (24.7) |
| 1 | 41 (25.3) |
| ≥ 2 | 19 (11.7) |
| N/A | 62 (38.3) |
| Prior lines of ET, N (%) | |
| 0 | 64 (39.5) |
| 1 | 36 (22.2) |
| 2 | 42 (25.9) |
| ≥ 3 | 20 (12.3) |
| Prior CDK4/6i, N (%) | 25 (15.4) |
| Prior lines of chemotherapy, median (range) | 1.0 (0–4) |
| Prior lines of chemotherapy, N (%) | |
| 0 | 56 (34.6) |
| 1 | 49 (30.2) |
| 2 | 41 (25.3) |
| ≥ 3 | 16 (9.9) |
| Previous chemotherapy agentsa, N (%) | |
| Taxane | 74 (45.7) |
| Epirubicin and cyclophosphamide | 38 (23.5) |
| Otherb | 69 (42.6) |
ER estrogen receptor, ET endocrine therapy, CDK4/6i cyclin-dependent kinases 4 and 6 inhibitors, CMF cyclophosphamidemethotrexate-5fluorouracil
aPrevious chemotherapy agents did not include neoadjuvant or adjuvant chemotherapy
bVinorelbine, Eribuline, CMF, Carboplatin/gemcitabine and anthracycline monotherapy